Biolase gets access to wider market in the US:
This article was originally published in Clinica
Executive Summary
In a move that expands the market for its products Biolase Technology has received US FDA approval to sell its LaserSmile dental laser as a treatment for periodontal disease. Previously cleared for just cosmetic and soft-tissue applications, the device can now be used to treat both early and advanced stages of periodontal disease, which the firm claims is a US first for a 810nm solid-state laser. More than 30% of adults over 50 years of age suffer from periodontal disease, said the San Clemente, California firm.